As part of our commitment to delivering innovative therapies to patients worldwide, Novartis believes in the need to support ethical independent clinical and non-clinical research conducted by qualified third-party investigators.
The value of the scientific research produced by third party sponsors is key to complementing Novartis-sponsored research by helping us to better understand the benefit/risk profile of our therapies, as well as enabling us to explore new opportunities addressing unmet medical needs.
The proposed research must offer meaningful scientific objectives and be supported by a valid study design. Privacy rights, safety and welfare of patients and animals shall be fully secured.
IITs are defined by Novartis as “studies with scientific and medical merit developed and sponsored by an independent investigator or academic sponsor. An IIT may be a clinical study conducted without the participation of Novartis, for which the IIT sponsor requests Novartis to provide either funding, drug product or both.”
IIRs are defined by Novartis as “non-clinical research conducted by an independent third-party sponsor to evaluate the effects, properties or profile of a Novartis drug that is conducted in animals or in vitro assays or utilizes previously collected human tissue*.”
Note: Any monetary request intended for a specified purpose to support medical/scientific research, education, policy initiatives, and patient advocacy activities, where Novartis will receive no benefit, should not be considered as IIT or IIR as these are classified as Grants. Read more information for Grants.